Rx Countermeasures: HHS Launching "Pivotal Studies" To Engage Industry
HHS is hoping to redefine its relationship with biotech and pharmaceutical firms that are developing Rx countermeasures though a series of "pivotal studies" under which government works more closely with industry at the beginning stages of development
You may also be interested in...
Agency to receive $170 million for regulatory sciences initiative in recognition of the need for smother development pathway for medical countermeasures.
While BARDA focuses on products, the new fund would support the viability of developers, NIAID Director Fauci says
As calls to develop novel antibiotics to treat drug-resistant bacteria grow louder, financial incentives remain a focus in the search for options to stimulate drug discovery